These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 19560355)

  • 1. Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I.
    Furet P; Schoepfer J; Radimerski T; Chène P
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4014-7. PubMed ID: 19560355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
    Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
    Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.
    Park H; Bahn YJ; Jeong DG; Woo EJ; Kwon JS; Ryu SE
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5372-6. PubMed ID: 18835158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
    Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
    Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
    Liang H; Wu X; Yalowich JC; Hasinoff BB
    Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIalpha and beta--distinct mode of action of two derivatives.
    Sai Krishna AD; Panda G; Kondapi AK
    Arch Biochem Biophys; 2005 Jun; 438(2):206-16. PubMed ID: 15907782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
    Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
    Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
    Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
    Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical structural motif for the catalytic inhibition of human topoisomerase II by UK-1 and analogs.
    Wang BB; Maghami N; Goodlin VL; Smith PJ
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3221-6. PubMed ID: 15149679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry.
    Cancilla MT; He MM; Viswanathan N; Simmons RL; Taylor M; Fung AD; Cao K; Erlanson DA
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3978-81. PubMed ID: 18579375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel homogenous assay for topoisomerase II action and inhibition.
    Jahnz M; Medina MA; Schwille P
    Chembiochem; 2005 May; 6(5):920-6. PubMed ID: 15812853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.
    Jiménez-Alonso S; Orellana HC; Estévez-Braun A; Ravelo AG; Pérez-Sacau E; Machín F
    J Med Chem; 2008 Nov; 51(21):6761-72. PubMed ID: 18816045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational design of novel glycomimetics: inhibitors of concanavalin A.
    Welch KT; Turner TA; Preast CE
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6573-5. PubMed ID: 18990567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-driven HtL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity.
    Stocks MJ; Barber S; Ford R; Leroux F; St-Gallay S; Teague S; Xue Y
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3459-62. PubMed ID: 15950471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of potent, selective protein kinase C inhibitors based on a phorbol skeleton.
    Yamatsugu K; Motoki R; Kanai M; Shibasaki M
    Chem Asian J; 2006 Sep; 1(3):314-21. PubMed ID: 17441066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.
    Park H; Bahn YJ; Ryu SE
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4330-4. PubMed ID: 19497739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based virtual screening: an application to human topoisomerase II alpha.
    Christmann-Franck S; Bertrand HO; Goupil-Lamy A; der Garabedian PA; Mauffret O; Hoffmann R; Fermandjian S
    J Med Chem; 2004 Dec; 47(27):6840-53. PubMed ID: 15615533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
    Charifson PS; Grillot AL; Grossman TH; Parsons JD; Badia M; Bellon S; Deininger DD; Drumm JE; Gross CH; LeTiran A; Liao Y; Mani N; Nicolau DP; Perola E; Ronkin S; Shannon D; Swenson LL; Tang Q; Tessier PR; Tian SK; Trudeau M; Wang T; Wei Y; Zhang H; Stamos D
    J Med Chem; 2008 Sep; 51(17):5243-63. PubMed ID: 18690678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monocyclic 4-amino-6-(phenylamino)-1,3,5-triazines as inhibitors of human DNA topoisomerase IIα.
    Pogorelčnik B; Brvar M; Zajc I; Filipič M; Solmajer T; Perdih A
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5762-5768. PubMed ID: 25453816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.